1 dysgeusia with some foods. We conclude that de-escalating the dose of radiation for HPV-positive patients by 30% and identifying which patients can safely be treated with this level of dose reduction warrants further study.
Introduction
Oropharyngeal squamous cell carcinoma (OPSCC) is a malignant tumor of the tonsil, tongue base, and/or oropharyngeal wall. Its incidence is increasing despite a decrease in all other head and neck cancers, which has been attributed to the declining prevalence of smoking. 1 Some of this increase appears to result from an increase in the incidence of human papillomavirus (HPV) infections. In 2016, an estimated 50,000 people were diagnosed with oropharyngeal cancer; an estimated 35,000 were related to HPV infection. 2 The demographics of HPV-positive and HPV-negative patients with OPSCC differ dramatically. HPV-positive patients generally present at a younger age, usually without a history of tobacco or alcohol use, and they have a better cancer prognosis. 2, 3 Despite these differences, the current treatment protocol for HPV-positive and HPV-negative OPSCC is basically the same. 1, 4, 5 Treatment generally involves definitive radiotherapy with chemotherapy, administered with the goal of avoiding surgery. However, surgery with adjuvant radiation (with or without chemotherapy) and postchemotherapy neck dissections are also used. These treatment regimens often exert a great toll on a patient's quality of life, with Abstract There is currently no clear distinction between the treatment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma (OPSCC) . HPV-positive OP-SCC has been demonstrated to be more radiosensitive than its HPV-negative counterpart. Despite this, patients with HPV-positive OPSCC continue to receive a full dose of radiation (70 Gy) outside clinical trials. However, this high dose comes with considerable morbidities, including severe mucositis, dysphagia, and xerostomia. We describe the cases of 2 patients with HPV-positive OPSCC who received two cycles of high-dose cisplatin at 100 mg/ m 2 on 3 separate days, along with concurrent radiotherapy at 50 Gy in 25 fractions for one and 46 Gy in 23 fractions for the other. During treatment, both patients experienced significant acute-phase toxicities-including grade 3 mucositis, grade 3 nausea, and grade 2 dermatitis-and their treatment regimen was stopped before its planned completion. Nevertheless, after a follow-up of 75 and 78 months, respectively, neither patient exhibited any evidence of disease. Late toxicities included grade 1 xerostomia, grade 1 pharyngeal-phase dysphagia, and grade 46% of patients experiencing acute grade 3 mucositis and dysphagia and 10% experiencing late grade 3 dysphagia and xerostomia. 6, 7 It has been postulated that HPV-positive patients may benefit from less intensive therapy to avoid unnecessary treatment-induced toxicity, and that is a current focus of research. 8 In this article, we describe our experience with lower-dose radiotherapy in 2 such patients.
Case reports Patient 1.
A 52-year-old man with a 3-pack-year history of smoking presented with a 6-month history of a painful mass on the left side of his neck. Computed tomography (CT) demonstrated left cervical lymphadenopathy (1.3 cm at level II and 2.4 cm at level III), subcentimeter lymph nodes along the inferior jugular chain and left posterior cervical chain, and a left tongue base mass measuring 1.7 × 1.3 × 4.1 cm. The results of a fine-needle biopsy were consistent with SCC, staining positive for p16.
Positron-emission tomography with fused CT (PET/ CT) revealed the presence of an 18F-fluorodeoxyglucose (FDG) -avid 2.0 × 2.5-cm primary tumor in the left tongue base along with metastases to multiple FDG-avid ipsilateral lymph nodes. Subcentimeter lymph nodes in levels II and III on the contralateral side were nonavid, and they were not believed to represent active disease. The final clinical staging was category T3N2bM0, stage IVA.
The proposed treatment regimen was three cycles of high-dose cisplastin at 100 mg/m 2 on days 1, 22, and 43 along with 70 Gy of radiation in 35 fractions of 2 Gy per fraction beginning on day 1. The initial radiotherapy target included the primary disease and the bilateral cervical nodal chains, which were to receive 50 Gy in 25 fractions. Gross disease with a 1-cm margin was to continue receiving radiotherapy to the full dose of 70 Gy. However, the patient experienced acute treatment toxicity in the form of grade 3 mucositis and grade 2 nausea in addition to thickened secretions and insomnia.
Before treatment, a percutaneous endoscopic gastrostomy (PEG) tube had been placed in anticipation of severe dysphagia. Despite this intervention, the patient experienced an 11-kg weight loss during treatment. He elected to stop treatment prematurely after two cycles of cisplatin and 50 Gy of radiation.
After the patient recovered from the acute side effects, PET/CT obtained 12 weeks post-treatment revealed that he had experienced a complete remission of his OPSCC, with no evidence of residual disease. He could begin eating by mouth 3 months after radiotherapy, and his PEG tube was removed 1 month later.
The patient returned to working full-time and was eating a normal diet, although he required some behav-ioral changes secondary to xerostomia and mild residual pharyngeal-phase dysphagia, which were diagnosed during a swallowing study. At 75 months of follow-up, which included CT and laryngoscopic examinations, he remained disease-free.
Patient 2. A 48-year-old man with no history of smoking presented with a 4-week history of a painless right neck mass. PET/CT demonstrated a 3.8 × 2.3-cm necrotic lymph node suspicious for carcinoma in the jugular digastric area and a 2.3 × 2.1-cm mass at the junction of the right tongue base and tonsillar area. He subsequently underwent a fine-needle aspiration biopsy and bilateral tonsillectomies. Pathology identified a basaloid SCC of the right tonsil that was positive for p16 on immunostaining. He was clinically staged at category T2N2aM0, stage IVA.
The patient's treatment regimen was to include three cycles of high-dose cisplatin at 100 mg/m 2 on days 1, 22, and 43. Also, the treatment plan called for 70 Gy of radiation in 35 fractions of 2 Gy per fraction to gross disease with a 1-cm margin, and 50 Gy of radiation in 25 fractions of 2 Gy per fraction to be administered to each side of the neck.
During treatment, the patient experienced acute toxicity, which included grade 3 mucositis, grade 3 nausea, grade 2 dermatitis, and reversible acute renal failure. In an effort to continue radiotherapy by making a field-size reduction, the boost portion of radiation that was directed to the gross disease was initiated when the total radiation dose reached 42 Gy instead of 50 Gy. Nevertheless, the patient elected to stop treatment after only 46 Gy had been delivered. He completed two of the three cycles of high-dose cisplatin.
After the patient recovered from the acute toxicity, he underwent an elective right modified radical neck dissection. The dissection was performed 6 weeks after radiotherapy had ended to treat residual enlarged cervical lymph nodes, the largest of which measured 3 cm on preoperative imaging. The pathologic specimens were negative for residual disease.
PET/CT obtained 16 weeks after the completion of radiotherapy revealed no evidence of active disease. The patient returned to work, and he was swallowing without difficulty and eating a normal diet with only a minor behavioral change necessary due to xerostomia. He did experience persistent dysgeusia with some foods, especially chocolate. At 78 months after the end of radiotherapy, he exhibited no evidence of disease.
Discussion
Controversy exists regarding the preferred course of therapy for HPV-related OPSCC. Traditionally, treatments have not been based on molecular mechanisms. Rather, they have been based on a combination of clinical trial evidence, patient preference, and professional recommendations regarding which modality is perceived to offer the best chance of cure while minimizing impairments in functional status. No clear distinctions have been made between the treatment of HPV-positive and HPV-negative OPSCC, as they are currently treated the same outside clinical trials.
The genes involved in cellular processes differ between the two forms of OPSCC. HPV-positive tumors are associated with wild-type p53, downregulation of pRB, and upregulation of p16; HPV-negative tumors are associated with mutations in p53, upregulation of pRB, and downregulation of p16. 9 Expression of p16 dramatically affects radiation sensitivity in OPSCC cells, since p16 overexpression impairs the recruitment of RAD51 to the site of DNA damage in HPV-positive cells by downregulating cyclin D1 protein expression. Furthermore, HPV-positive tumors exhibit a lower percentage of cells with CD44 and CD98 expression than do HPV-negative tumors, which may also account for the difference in radiation sensitivity between the two types of OPSCC. 10 Patients with a high percentage of CD98-positive tumor cells have been shown to have a significantly worse 5-year overall survival than patients with a low percentage.
In addition, patients with HPV-positive OPSCC have demonstrated a better adaptive immune response in several studies. An elevated percentage of CD8 cells and a low CD4:CD8 ratio in these patients has been correlated with a better response to radiation and longer disease-free survival. 11 The enhanced responsiveness of HPV-positive cancer cells to radiotherapy might be attributable to cell cycle dysregulation and impaired DNA repair. Compared with HPV-negative cell lines, irradiated HPV-positive cell lines progress faster through the S phase and exhibit a more distinct accumulation in G2/M. The abnormal cell cycle checkpoint activation is accompanied by a more pronounced increase in cell death after irradiation and a higher number of residual and unreleased double-strand breaks than what is seen with HPV-negative cells. 12 The enhanced responsiveness of HPV-positive OPSCC to radiotherapy has led to trials exploring whether reducing the dose of radiation for HPV-positive OPSCC maintains efficacy. An ongoing phase II trial has found that reducing the radiation dose in patients who respond well to induction chemotherapy did not compromise 1-year progression-free survival. 13 Patients who achieved a complete response received radiation up to 54 Gy plus cetuximab. All patients who showed a partial response or stable disease received the standard 70-Gy dose of radiotherapy plus cetuximab.
Generally, cisplatin is used in the treatment of OP-SCC, but several preliminary studies have shown that cetuximab exerts similar efficacy without as many toxicities. 10 It remains unknown how cetuximab plays a role in radiosensitizing HPV-positive OPSCC, but it has been shown that it is associated with a favorable outcome and that HPV oncogenes do not modulate the anti-EGFR antibody response in OPSCC. 10, 14, 15 One study showed that 1-year progression-free survival was 91% among patients receiving 54 Gy and 87% for those receiving the standard dose. 13 Another recent study found that de-escalating the dose of radiotherapy to involved lymph nodes in HPV-positive OPSCC from a range of 70 to 74.4 Gy down to a range of 56.4 to 59.8 Gy did not compromise 5-year locoregional control, disease-free survival, or overall survival. 16 This dose reduction occurred independent of whether patients experienced a good response to induction chemotherapy.
There are at least seven ongoing phase II trials and one ongoing phase III trial looking at dose reduction; six of these trials involve de-escalation of radiotherapy (table). If they show that a de-escalated radiotherapy dose maintains efficacy, our case reports suggest that even lower doses should be studied in some patients, since our patients received 50 and 46 Gy, respectively, and experienced at least 6 years of disease-free survival.
An ongoing phase II trial is looking at reducing the dose to 50 Gy, but only after, not instead of, surgery (Elie E, phase II randomized trial of transoral surgical resection followed by low-dose or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer, Eastern Cooperative Oncology Group, Protocol E3311, 2016).
It is not unreasonable to explore the possibility of treating patients with these low doses of radiation since anal cancer is currently being treated with 54 Gy plus chemotherapy and is being sterilized about 70% of the time. 17, 18 A similar low-dose regimen of radiotherapy may become the standard treatment for HPV-positive OPSCC if responses and survival rates are maintained.
Identifying which patients would best respond to treatment de-escalation would be an interesting avenue to explore. Currently, there is no evidence available to identify such a subset of patients. However, it may be worth examining if patients with biomarkers for a good response to therapy would benefit from dose de-escalation. For example, as mentioned previously, patients with a lower percentage of CD44 and CD98 cells have been shown to have a significantly better 5-year overall survival than do patients with a higher percentage of these cells. 10 Study designers could select patients with the lower percentages for a significant treatment de-escalation study.
More research also should be done to identify other biomarkers that might predict a patient's response to therapy. Also, studies have found that survival rates are liu, golDenbeRg, alMokaDeM, CRisT, MaCkley lower among HPV-positive patients who smoke than in those who do not, even in patients with recurrent tumors. 19, 20 Thus, it may be important to exclude patients who smoke from treatment de-escalation studies because they might not respond as well to a de-escalated dose.
There are many risks associated with treatment de-escalation, so these kinds of studies should be reserved only for a well-justified clinical trial. First and foremost, the risk of progressive disease is the main concern surrounding treatment de-escalation. OPSCC can invade the surrounding normal tissue and spread both lymphogenously and hematogenously, so some patients may develop metastatic disease in the setting of a treatment de-escalation study. Furthermore, while HPV-positive OPSCC has been shown to be more radiosensitive than its HPV-negative counterpart, this has not been shown to improve overall survival or progression-free survival in the definitive setting. Thus, there is a chance that some patients may have a worse prognosis as a result of entering a treatment de-escalation study.
While our experience provides evidence to support a de-escalation of radiotherapy in the treatment of HPV-positive OPSCC, there are limitations to our findings. First, our findings were based on only 2 cases, and a comparison group was not available. De-escalation needs to be prospectively validated in a clinical trial. Also, while our 2 patients received an approximate 30% reduction in radiotherapy dose, they still experienced significant acute toxicities. Both patients experienced acute grade 3 mucositis, and patient 2 also experienced acute grade 3 nausea. For such a significant reduction in radiotherapy dose, we would have expected more of a reduction in the incidence of acute grade 3 toxicities. Nevertheless, the 2 patients did have very manageable late toxicities, and both were able to swallow and eat a normal diet on follow-up. 
